3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
2
Completed
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Stomach Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Irritable Bowel Syndrome
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Diseases
1
Gastroesophageal Reflux
1
Brain Neoplasms
1
Barrett Esophagus
1
Adenomatous Polyps
1
Interventions
Temozolomide
28
Radiosurgery
19
Radiotherapy
17
Bevacizumab
12
Magnetic Resonance Spectroscopy
9
Radiation
6
Erlotinib Hydrochloride
6
Carboplatin
6
Topotecan
5
Nivolumab
5
Mental Status and Dementia Tests
5
Irinotecan
5
Capecitabine
5
pembrolizumab
4
dabrafenib
4
Trastuzumab
4
Sunitinib
4
Pemetrexed
4
Ipilimumab
4
Filgrastim
4
Cyclophosphamide
4
Aminolevulinic Acid
4
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
4
cabozantinib
3
Vorinostat
3
TPI-287
3
Specimen Handling
3
Radiotherapy, Intensity-Modulated
3
Methylphenidate
3
Lomustine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Brain Neoplasms
×
Fluorescein
×
Clear all
NCT02028325
2016-11-08
Fluorescein
Indiana University
Phase 4
Terminated
136 enrolled
4 charts